ABBV ▼ -2.4% - AbbVie Inc.
$ABBV - AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease
13-OCT-2026 03:15 PM ET
Share this post
More filings for $ABBV
ABBV ▲ +1.5% - AbbVie Inc.Oct 11, 2026ABBV ▲ +0.6% - AbbVie Inc.Oct 7, 2026ABBV ▲ +0.6% - AbbVie Inc.Oct 5, 2026ABBV ▼ -0.1% - AbbVie Inc.Oct 1, 2026ABBV ▼ -0.0% - AbbVie Inc.Oct 1, 2026ABBV ▼ -1.2% - AbbVie Inc.Sep 30, 2026
View full $ABBV filing history →💬 Comments
Loading comments…
Leave a comment